# Transverse Medical Inc

> Transverse Medical is a Denver medical-device company developing POINT-GUARD, an investigational cerebral embolic protection system intended to cover all three great vessels that supply blood to the brain during TAVR and other structural-heart procedures. Its immediate customers would be interventional cardiologists and hospitals, but the device remains in clinical development and is not cleared for sale.

- **Founded:** 2011
- **Headquarters:** Denver, United States
- **Founders:** J. Eric Goslau (Co-Founder, President and CEO)
- **Team size:** Approximately 12-15 employees
- **Products:** POINT-GUARD Cerebral Embolic Protection Device
- **Notable:** Developed a patent portfolio covering catheter-based filter apparatuses, including US patents granted in 2018, 2022 and 2024., Completed first-in-human work with the first-generation POINT-GUARD in Germany before redesigning the system., Completed design development for a next-generation POINT-GUARD intended to improve sealing, stability and anatomical fit.

## Products & services

- **POINT-GUARD Cerebral Embolic Protection Device** — An investigational, catheter-delivered filter system designed to cover all three major aortic arch vessels, intercept embolic debris during TAVR, accommodate varied arch anatomy, and avoid interference with the primary procedure.

## Achievements

- Developed a patent portfolio covering catheter-based filter apparatuses, including US patents granted in 2018, 2022 and 2024.
- Completed first-in-human work with the first-generation POINT-GUARD in Germany before redesigning the system.
- Completed design development for a next-generation POINT-GUARD intended to improve sealing, stability and anatomical fit.
- Registered the prospective, single-arm, multicenter GUARDIAN feasibility study (NCT06962371).
- Completed the first series of feasibility-study patients at Victorian Heart Hospital in Melbourne in 2025.
- Raised more than $10 million in Series B2 financing to support clinical validation, team growth and FDA IDE preparation.
- Added former Boston Scientific global chief medical officer Ian T. Meredith to the board in 2024.

## Latest updates

- **2026-06** — Appointed Thomas E. Chilcott, a healthcare finance executive and CPA, as chief financial officer.
- **2026-03** — CEO Eric Goslau joined an LSI USA panel on advancing neurovascular medical solutions through the startup lifecycle.
- **2025-04** — Closed a Series B2 financing of more than $10 million for clinical validation, infrastructure and FDA IDE preparation.
- **2025-04** — Reported completion of the first series of patients in the POINT-GUARD feasibility study at Victorian Heart Hospital.
- **2024-10** — Appointed Ian T. Meredith, former Boston Scientific EVP and global chief medical officer, to the board.

## Links

- Website: https://www.transversemedical.com
- LinkedIn: https://www.linkedin.com/company/transverse-medical-inc

---

Profile page: https://yespress.io/transverse-medical-inc
Published by YesPress — https://yespress.io
Last updated: 2026-08-18